A Review Desk, Not a Dispensary

What Peptide Coalition is

Peptide Coalition is an independent editorial desk that reads the published literature on research peptides and writes it up in plain English with the citations attached. It sells nothing, stocks nothing, and has no commercial relationship with any manufacturer, pharmacy, clinic or supplier of any compound discussed on it.

The name describes the method rather than an organisation. A coalition is a set of parties that do not share an interest but do share a problem, and that is a fair description of the five compounds gathered here: BPC-157, CJC-1295, semaglutide, thymosin alpha-1 and PT-141 have nothing pharmacological in common and one constraint entirely in common. Reading them together is only worthwhile because of the second fact.

The organising thesis, stated plainly

Most cross-compound peptide writing is a survey: five entries, five summaries, no argument. This desk makes an argument instead, and it is falsifiable.

The claim is that a peptide's persistence in circulation is the single most predictive fact about it — not of what it does, but of what can ever be known about it. Duration sets the dosing format. The dosing format sets which trial designs are operationally possible. The trial design sets which endpoints are reachable, which in turn sets whether a regulator could ever have something to approve. The same number also sets the timing and persistence of the adverse-effect profile, which is why a compound carried on albumin for days produces complaints that last days, and a compound cleared in hours produces complaints that resolve in hours.

The thesis has a stated boundary, and the cross-class matrix closes with it. Duration explains the shape of a literature. It explains nothing about mechanism, and nothing about whether the evidence in that literature is any good.

How a page here is assembled

Every factual claim on this site traces to a numbered entry in the bibliography, and every quantitative statement — a percentage, a hazard ratio, an enrolment figure, a half-life — carries the citation it came from. Where a study reports a confidence interval or a P value, those are reproduced rather than rounded away, because an effect that is statistically detectable and clinically small is a different thing from an effect that is large, and the difference lives in those numbers.

Community-reported experience is included, because pretending it does not exist would misrepresent how these compounds are actually discussed. It is always labelled as anecdotal and never carries a dose. It is kept in its own section, below the published findings, so that no reader can mistake one for the other.

Where the literature is negative, the negative result is reported in the same register as a positive one. The largest and most rigorous trial of thymosin alpha-1 found no mortality benefit in sepsis ^[18], and that appears on its page, in its abstract, and in the matrix.

Three things this desk will not do

It will not recommend a dose, a schedule or a route to anyone, for any compound, in any circumstance. Describing what investigators administered in a published study is reporting; suggesting what a reader should take is practising medicine without a licence or a patient, and this desk does neither.

It will not sell, source, or help locate any compound. Two of the five reviewed here are approved prescription medicines that require a prescriber. Two are approved nowhere, and material sold under their names carries no verification of identity, purity or concentration — a fact repeated on every page for the good reason that it keeps being the most important one.

It will not imply that regulatory status is a scientific verdict. Thymalfasin is approved in more than thirty-five countries and not in the United States ^[19]; BPC-157 has a large and internally consistent animal literature and no approval anywhere ^[2][4][5]. Approval tracks whether a sponsor could run an approvable trial, which tracks the problems this site is about. It is not a scoreboard.